eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

Rhea-AI Summary

eXoZymes (NASDAQ:EXOZ) will host a Q3 2025 operational update webinar at 5:00 PM ET on November 13, 2025 covering results through the quarter ended October 31, 2025. Management will review commercialization progress, recent hires, and near-term milestones.

Q3 highlights: net loss of $2.29 million (quarter), year-to-date loss of $6.5 million, operating expenses up $0.9 million versus prior year, and $5.1 million cash on hand, described as supporting operations into early Q2 2026. Company named Amy Lunzer chief of staff and promoted co-founder Tyler Korman, PhD to chief scientific officer. A recording and live webcast will be available on investor relations.

Positive

• Appointment of Tyler Korman as Chief Scientific Officer
• Appointment of Amy Lunzer as Chief of Staff
• NCTx subsidiary progressing exploratory analog and parallel asset programs

Negative

• Quarterly net loss of $2.29 million
• YTD net loss of $6.5 million
• Operating expenses increased by $0.9 million versus prior year
• Cash on hand $5.1 million, runway into early Q2 2026

Management to host Q3 2025 update at 5:00PM Eastern Time, today.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended October 31, 2025.

Michael Heltzen, CEO of eXoZymes, states, "Since our last quarterly update, we have worked diligently on maturing our core assets - both scientifically as well as commercially - including what the ideal go-to market strategies are for each of these. We look forward to sharing these details with our investors on the call today."

Third quarter 2025 highlights:

• Commercialization: Purpose-built subsidiary, NCTx, continues to develop including an exploratory analog program intended to support potential future nutraceutical or pharmaceutical opportunities - contingent on further development, validation, regulatory processes, and commercialization outcomes. Additionally, two other assets - one for santalene and another for non-intoxicating cannabinoids - are being developed in parallel.

• Strategic Investment: Operating expenses rose by $0.9 million for the quarter compared to prior year. The Net loss for the quarter was $2.29 million with a year to date loss of $6.5 million The additional spend was primarily due to expanded R&D and leadership hires to drive long-term growth. Ended Q2 2025 with $5.1 million in cash and cash equivalents, supporting operations into the beginning of Q2, 2026.

• Solidifying team: Appointing Amy Lunzer - an accomplished business, supply-chain, and operations executive - as the Chief of Staff as well as announcing that co-founder of eXoZymes and cell-free biomanufacturing pioneer, Tyler Korman, PhD, as the Chief Scientific Officer.

Investors and interested parties can access the live webinar, at the time of the event through eXoZymes' investor relations website. A recording of the conference call will also be made publicly available soon after the live call.

Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.

About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce very valuable natural products, via a commercially scalable, sustainable, and eco-friendly alternative: exozymes.

Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.

While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.

Learn more on exozymes.com

eXoZymes Safe Harbor

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com

https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes

SOURCE: eXoZymes

View the original press release on ACCESS Newswire

FAQ

When is eXoZymes (EXOZ) hosting the Q3 2025 update webinar?

The webcast is scheduled for 5:00 PM ET on November 13, 2025.

What were eXoZymes' reported losses in Q3 2025 and YTD 2025?

The company reported a $2.29 million net loss for Q3 2025 and $6.5 million year-to-date.

How much cash did eXoZymes report at the end of Q2 2025 and how long is runway?

Cash and equivalents were $5.1 million, described as supporting operations into early Q2 2026.

What drove the higher operating spend at eXoZymes in Q3 2025?

Operating expenses rose by $0.9 million, primarily for expanded R&D and leadership hires.

What commercialization programs did eXoZymes highlight for Q3 2025?

The company cited its NCTx subsidiary, an exploratory analog program, santalene work, and non-intoxicating cannabinoid asset development.

Will eXoZymes make the Q3 2025 webinar available after the live event?

Yes, a recording will be made publicly available soon after the live webcast on investor relations.